15 תוצאות
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, including pharmaceutical compositions and uses thereof, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity.
BACKGROUND OF THE INVENTION
The estrogen
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, including pharmaceutical compositions and uses thereof, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity.
BACKGROUND OF THE INVENTION
The estrogen
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, including pharmaceutical compositions and uses thereof, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity.
BACKGROUND OF THE INVENTION
The estrogen
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, including pharmaceutical compositions and uses thereof, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity.
BACKGROUND OF THE INVENTION
The estrogen
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, including pharmaceutical compositions and uses thereof, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity.
BACKGROUND OF THE INVENTION
The estrogen
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, and to compounds for inhibiting cytokines, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity, as well as to pharmaceutical compositions and methods
FIELD OF THE INVENTION
The present invention relates to veterinary medicine, in particular to the treatment and/or prevention of metabolic disorders in canine animals.
BACKGROUND OF THE INVENTION
Canine animals, e.g. dogs, are affected by various metabolic disorders. A number of metabolic disorders
FIELD OF INVENTION
The present invention relates to a method of making novel dipeptidyl peptidase-IV ("DPP-IV`) inhibitor compounds and a method of making 3,3,4,4-tetrafluoropyrrolidine, a starting material utilized in the afore-mentioned method for preparing DPP-IV compounds.
BACKGROUND OF
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention concerns the systemic administration of an inhibitor of fatty acid synthase (E.C. 2.3.1.85, FAS) by any suitable route to achieve weight loss and/or reduction of adipocyte mass without significant toxicity. Use of FAS inhibitors
FIELD OF THE INVENTION
The present invention relates to compounds which are inhibitors of sodium dependent glucose co-transporter-2 (SGLT-2), methods of making them, and uses thereof.
BACKGROUND OF THE INVENTION
According to the World Health Organization (WHO), in 2009, more than 220 million people
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
The research and development of the invention described below was not federally sponsored.
BACKGROUND OF THE INVENTION
The peroxisome proliferator-activated receptors (PPARs) are considered to be metabolic sensors regulating the
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
The research and development of the invention described below was not federally sponsored.
BACKGROUND OF THE INVENTION
The peroxisome proliferator-activated receptors (PPARs) are considered to be metabolic sensors regulating the
BACKGROUND
Resveratrol (3,4',5-trihydroxystilbene) (FIG. 1) is a naturally occurring phytoalexin produced by a variety of plants in response to stress. Resveratrol has wide pharmacological applications and is being investigated for the treatment of numerous conditions and/or disorders, such as
BACKGROUND
Resveratrol (3,4',5-trihydroxystilbene) (FIG. 1) is a naturally occurring phytoalexin produced by a variety of plants in response to stress. Resveratrol has wide pharmacological applications and is being investigated for the treatment of numerous conditions and/or disorders, such as
FIELD OF THE INVENTION
The present invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV (hereinafter "DPP-IV"), pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with